What Happened?
Needham, MA-based Candel Therapeutics Appointed Seshu Tyagarajan as Chief Technical and Development Officer
About the Company
Also known as Advantagene. Inc., we are a Massachusetts-based biotechnology company developing our proprietary immuno-oncology platforms for the treatment of solid tumors, including our Gene Mediated Cytotoxic (GMCI™) platform and our rQNestin34.5 platform. GMCI™ is an "off-the-shelf" immunotherapy designed to generate a personalized, robust, and precise systemic response from the patient's own immune system against his or her cancer.
About the Person
Seshu Tyagarajan is Chief Technical and Development Officer at Candel Therapeutics. Previously, Seshu held various senior IT leadership roles in the industry.
Info Source
News
Short Profile